- Moderna Inc MRNA has signed a memorandum of understanding, a non-legally binding agreement with the Canadian government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility.
- While the details are not disclosed, the idea is to eventually use the site to supply Canada with direct access to rapid pandemic response capabilities, including the Company's two-dose COVID-19 vaccine.
- Other than the COVID-19 jab, Moderna could also use the new facility to provide Canadians with a portfolio of vaccines against other respiratory diseases, such as seasonal influenza and respiratory syncytial virus.
- Moderna's outstanding 2021 orders for the COVID-19 vaccine are now worth about $20 billion. It has promised to deliver 44 million doses of its pandemic jab to Canada.
- Price Action: MRNA shares are down 2.53% at $472.22 during the market session on the last check Tuesday.
- Photo by Daniel Schludi on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in